A Naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity

Molecular and Cellular Biology

Volumn 34, Issue 19, 2014, Pages 3618-3629

  Mohammad, Sameer ^a   Patel, Rajesh T ^a   Bruno, Joanne ^a,c   Panhwar, Muhammad Siyab ^b   Wen, Jennifer ^a   McGraw, Timothy E ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; HORMONE RECEPTOR;

ADIPOCYTE; ADIPOSE TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CELL COMPARTMENTALIZATION; CELL MEMBRANE; DESENSITIZATION; DOWN REGULATION; HUMAN; HUMAN CELL; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; KINETICS; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; 3T3 CELL LINE; ANIMAL; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; GOLGI COMPLEX; HEK293 CELL LINE; METABOLISM; MOUSE; PHYSIOLOGY; PROTEIN TRANSPORT;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CARDIOVASCULAR DISEASES; CELL MEMBRANE; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GENE EXPRESSION REGULATION; GENETIC VARIATION; GOLGI APPARATUS; HEK293 CELLS; HUMANS; INSULIN RESISTANCE; MICE; PROTEIN TRANSPORT; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 84906956323     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00256-14     Document Type: Article

References (69)

1. Dupre J, Ross SA, Watson D, Brown JC. 1973. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 37:826-828. http://dx.doi.org/10.1210/jcem-37-5-826.
2. Ross SA, Dupre J. 1978. Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects. Diabetes 27:327-333. http: //dx.doi.org/10.2337/diab.27.3.327.
3. Vilsboll T, Krarup T, Madsbad S, Holst JJ. 2003. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul. Pept. 114:115-121. http://dx.doi.org/10.1016/S0167-0115(03)00111-3.
4. Drucker DJ. 2006. The biology of incretin hormones. Cell Metab. 3:153-165. http://dx.doi.org/10.1016/j.cmet.2006.01.004.
5. McIntyre N, Holdsworth CD, Turner DS. 1965. Intestinal factors in the control of insulin secretion. J. Clin. Endocrinol. Metab. 25:1317-1324. http://dx.doi.org/10.1210/jcem-25-10-1317.
6. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y. 2002. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8:738-742. http://dx .doi.org/10.1038/nm727.
7. Asmar M, Simonsen L, Madsbad S, Stallknecht B, Holst JJ, Bulow J. 2010. Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes 59:2160-2163. http://dx.doi.org/10.2337/db10-0098.
8. Asmar M, Simonsen L, Arngrim N, Holst JJ, Dela F, Bulow J. 2014. Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects. Int. J. Obes. 38:259-265. http://dx.doi.org/10.1038/ijo.2013.73.
9. Mohammad S, Ramos LS, Buck J, Levin LR, Rubino F, McGraw TE. 2011. Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110beta isoform of phosphatidylinositol 3-kinase. J. Biol. Chem. 286:43062-43070. http://dx.doi.org/10.1074/jbc.M111.289009.
10. Yip RG, Boylan MO, Kieffer TJ, Wolfe MM. 1998. Functional GIP receptors are present on adipocytes. Endocrinology 139:4004-4007. http: //dx.doi.org/10.1210/endo.139.9.6288.
11. Starich GH, Bar RS, Mazzaferri EL. 1985. GIP increases insulin receptor affinity and cellular sensitivity in adipocytes. Am. J. Physiol. 249:E603- E607.
12. Getty-Kaushik L, Song DH, Boylan MO, Corkey BE, Wolfe MM. 2006. Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity 14:1124-1131. http://dx.doi.org/10 .1038/oby.2006.129.
13. Zhou H, Yamada Y, Tsukiyama K, Miyawaki K, Hosokawa M, Nagashima K, Toyoda K, Naitoh R, Mizunoya W, Fushiki T, Kadowaki T, Seino Y. 2005. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochem. Biophys. Res. Commun. 335:937-942. http://dx.doi.org/10.1016/j.bbrc.2005.07.164.
14. Tseng CC, Zhang XY. 2000. Role of G protein-coupled receptor kinases in glucose-dependent insulinotropic polypeptide receptor signaling. Endocrinology 141:947-952. http://dx.doi.org/10.1210/endo.141.3.7365.
15. Kim W, Egan JM. 2008. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev. 60:470-512. http://dx.doi.org/10 .1124/pr.108.000604.
16. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. 1993. Preserved incretin activity of glucagon-like peptide-1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91:301-307. http://dx .doi.org/10.1172/JCI116186.
17. Elahi D, Mcaloondyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK. 1994. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (Gip) and glucagon- like peptide-1(7-37) in normal and diabetic subjects. Regul. Pept. 51:63-74. http://dx.doi.org/10.1016/0167-0115(94)90136-8.
18. Fritsche A, Stefan N, Hardt E, Haring H, Stumvoll M. 2000. Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetologia 43: 852-858. http://dx.doi.org/10.1007/s001250051461.
19. Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, Lyssenko V, Bouatia-Naji N, Dupuis J, Jackson AU, Kao WH, Li M, Glazer NL, Manning AK, Luan J, Stringham HM, Prokopenko I, Johnson T, Grarup N, Boesgaard TW, Lecoeur C, Shrader P, O'Connell J, Ingelsson E, Couper DJ, Rice K, Song K, Andreasen CH, Dina C, Kottgen A, Le Bacquer O, Pattou F, Taneera J, Steinthorsdottir V, Rybin D, Ardlie K, Sampson M, Qi L, van Hoek M, Weedon MN, Aulchenko YS, Voight BF, Grallert H, Balkau B, Bergman RN, Bielinski SJ, Bonnefond A, Bonnycastle LL, Borch-Johnsen K, Bottcher Y, et al. 2010. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat. Genet. 42:142-148. http://dx.doi .org/10.1038/ng.521.
20. Hu C, Zhang R, Wang C, Wang J, Ma X, Hou X, Lu J, Yu W, Jiang F, Bao Y, Xiang K, Jia W. 2010. Variants from GIPR, TCF7L2, DGKB, MADD, CRY2, GLIS3, PROX1, SLC30A8 and IGF1 are associated with glucose metabolism in the Chinese. PLoS One 5:e15542. http://dx.doi.org /10.1371/journal.pone.0015542.
21. Nitz I, Fisher E, Weikert C, Burwinkel B, Li Y, Mohlig M, Boeing H, Schreiber S, Schrezenmeir J, Doring F. 2007. Association analyses of GIP and GIPR polymorphisms with traits of the metabolic syndrome. Mol. Nutr. Food Res. 51:1046-1052. http://dx.doi.org/10.1002/mnfr.200700048.
22. Sauber J, Grothe J, Behm M, Scherag A, Grallert H, Illig T, Hinney A, Hebebrand J, Wiegand S, Gruters A, Krude H, Biebermann H. 2010. Association of variants in gastric inhibitory polypeptide receptor gene with impaired glucose homeostasis in obese children and adolescents from Berlin. Eur. J. Endocrinol. 163:259-264. http://dx.doi.org/10.1530 /EJE-10-0444.
23. Almind K, Ambye L, Urhammer SA, Hansen T, Echwald SM, Holst JJ, Gromada J, Thorens B, Pedersen O. 1998. Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells. Diabetologia 41:1194-1198.
24. Karylowski O, Zeigerer A, Cohen A, McGraw TE. 2004. GLUT4 is retained by an intracellular cycle of vesicle formation and fusion with endosomes. Mol. Biol. Cell 15:870-882. http://dx.doi.org/10.1091/mbc .E03-07-0517.
25. Zeigerer A, McBrayer MK, McGraw TE. 2004. Insulin stimulation of GLUT4 exocytosis, but not its inhibition of endocytosis, is dependent on RabGAP AS160. Mol. Biol. Cell 15:4406-4415. http://dx.doi.org/10.1091 /mbc.E04-04-0333.
26. Lampson MA, Racz A, Cushman SW, McGraw TE. 2000. Demonstration of insulin-responsive trafficking of GLUT4 and vpTR in fibroblasts. J. Cell Sci. 113(Part 22):4065-4076.
27. Martin OJ, Lee A, McGraw TE. 2006. GLUT4 distribution between the plasma membrane and the intracellular compartments is maintained by an insulin-modulated bipartite dynamic mechanism. J. Biol. Chem. 281: 484-490. http://dx.doi.org/10.1074/jbc.M505944200.
28. Zeigerer A, Lampson MA, Karylowski O, Sabatini DD, Adesnik M, Ren M, McGraw TE. 2002. GLUT4 retention in adipocytes requires two intracellular insulin-regulated transport steps. Mol. Biol. Cell 13:2421-2435. http://dx.doi.org/10.1091/mbc.E02-02-0071.
29. Lampson MA, Schmoranzer J, Zeigerer A, Simon SM, McGraw TE. 2001. Insulin-regulated release from the endosomal recycling compartment is regulated by budding of specialized vesicles. Mol. Biol. Cell 12: 3489-3501. http://dx.doi.org/10.1091/mbc.12.11.3489.
30. Hannan S, Wilkins ME, Dehghani-Tafti E, Thomas P, Baddeley SM, Smart TG. 2011. Gamma-aminobutyric acid type B (GABA(B)) receptor internalization is regulated by the R2 subunit. J. Biol. Chem. 286:24324- 24335. http://dx.doi.org/10.1074/jbc.M110.220814.
31. Hannan S, Wilkins ME, Thomas P, Smart TG. 2013. Tracking cell surface mobility of GPCRs using alpha-bungarotoxin-linked fluorophores. Methods Enzymol. 521:109-129. http://dx.doi.org/10.1016/B978 -0-12-391862-8.00006-5.
32. Gault VA, Flatt PR, Bailey CJ, Harriott P, Greer B, Mooney MH, O'Harte FP. 2002. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucosedependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochem. J. 367: 913-920. http://dx.doi.org/10.1042/BJ20020319.
33. Gespach C, Emami S, Rosselin G. 1984. Gastric inhibitory peptide (GIP), pancreatic glucagon and vasoactive intestinal peptide (VIP) are cAMPinducing hormones in the human gastric cancer cell line HGT-1. Homologous desensitization of VIP receptor activity. Biochem. Biophys. Res. Commun. 120:641-649.
34. Tobin AB, Butcher AJ, Kong KC. 2008. Location, location, location. Site-specific GPCR phosphorylation offers a mechanism for cell-typespecific signalling. Trends Pharmacol. Sci. 29:413-420. http://dx.doi.org /10.1016/j.tips.2008.05.006.
35. Butcher AJ, Prihandoko R, Kong KC, McWilliams P, Edwards JM, Bottrill A, Mistry S, Tobin AB. 2011. Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code. J. Biol. Chem. 286: 11506-11518. http://dx.doi.org/10.1074/jbc.M110.154526.
36. Sekine-Aizawa Y, Huganir RL. 2004. Imaging of receptor trafficking by using alpha-bungarotoxin-binding-site-tagged receptors. Proc. Natl. Acad. Sci. U. S. A. 101:17114-17119. http://dx.doi.org/10.1073/pnas .0407563101.
37. Hausdorff WP, Caron MG, Lefkowitz RJ. 1990. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J. 4:2881- 2889.
38. Lefkowitz RJ, Wessels MR, Stadel JM. 1980. Hormones, receptors, and cyclic AMP: their role in target cell refractoriness. Curr. Top. Cell. Regul. 17:205-230. http://dx.doi.org/10.1016/B978-0-12-152817-1.50011-0.
39. Stadel JM, Lefkowitz RJ. 1980. Molecular mechanisms of beta-adrenergic receptor desensitization. Proc. West. Pharmacol. Soc. 23:469-475.
40. Luttrell LM, Lefkowitz RJ. 2002. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci. 115:455-465.
41. Shankaran H, Wiley HS, Resat H. 2007. Receptor downregulation and desensitization enhance the information processing ability of signalling receptors. BMC Syst. Biol. 1:48. http://dx.doi.org/10.1186/1752-0509-1-48.
42. Ferguson SS, Barak LS, Zhang J, Caron MG. 1996. G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. Can. J. Physiol. Pharmacol. 74:1095-1110. http://dx.doi.org/10.1139 /y96-124.
43. Penn RB, Pronin AN, Benovic JL. 2000. Regulation of G protein-coupled receptor kinases. Trends Cardiovasc. Med. 10:81-89. http://dx.doi.org/10 .1016/S1050-1738(00)00053-0.
44. Aramori I, Ferguson SS, Bieniasz PD, Zhang J, Cullen B, Cullen MG. 1997. Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. EMBO J. 16:4606-4616. http://dx.doi.org/10 .1093/emboj/16.15.4606.
45. Kelly E, Bailey CP, Henderson G. 2008. Agonist-selective mechanisms of GPCR desensitization. Br. J. Pharmacol. 153(Suppl 1):S379-S388. http: //dx.doi.org/10.1038/sj.bjp.0707604.
46. Magalhaes AC, Dunn H, Ferguson SS. 2012. Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. Br. J. Pharmacol. 165:1717-1736. http://dx.doi.org/10.1111/j.1476-5381.2011.01552.x.
47. Ritter SL, Hall RA. 2009. Fine-tuning of GPCR activity by receptorinteracting proteins. Nat. Rev. Mol. Cell Biol. 10:819-830. http://dx.doi .org/10.1038/nrm2803.
48. Galet C, Hirakawa T, Ascoli M. 2004. The postendocytotic trafficking of the human lutropin receptor is mediated by a transferable motif consisting of the C-terminal cysteine and an upstream leucine. Mol. Endocrinol. 18:434-446. http://dx.doi.org/10.1210/me.2003-0293.
49. Mohammad S, Baldini G, Granell S, Narducci P, Martelli AM, Baldini G. 2007. Constitutive traffic of melanocortin-4 receptor in Neuro2A cells and immortalized hypothalamic neurons. J. Biol. Chem. 282:4963-4974. http://dx.doi.org/10.1074/jbc.M608283200.
50. Gilliland CT, Salanga CL, Kawamura T, Trejo J, Handel TM. 2013. The chemokine receptor CCR1 is constitutively active, which leads to G protein- independent, beta-arrestin-mediated internalization. J. Biol. Chem. 288:32194-32210. http://dx.doi.org/10.1074/jbc.M113.503797.
51. Grimsey NL, Goodfellow CE, Dragunow M, Glass M. 2011. Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. Biochim. Biophys. Acta 1813:1554-1560. http://dx.doi.org/10.1016/j.bbamcr.2011.05.010.
52. Snyder JC, Rochelle LK, Lyerly HK, Caron MG, Barak LS. 2013. Constitutive internalization of the leucine-rich G protein-coupled receptor- 5 (LGR5) to the trans-Golgi network. J. Biol. Chem. 288:10286- 10297. http://dx.doi.org/10.1074/jbc.M112.447540.
53. Trivedi RR, Bhattacharyya S. 2012. Constitutive internalization and recycling of metabotropic glutamate receptor 5 (mGluR5). Biochem. Biophys. Res. Commun. 427:185-190. http://dx.doi.org/10.1016/j.bbrc.2012 .09.040.
54. von Zastrow M. 2001. Endocytosis and downregulation of G proteincoupled receptors. Parkinsonism Relat. Disord. 7:265-271. http://dx.doi .org/10.1016/S1353-8020(00)00069-9.
55. Tseng CC, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM. 1996. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J. Clin. Invest. 98:2440- 2445.
56. Lyssenko V, Eliasson L, Kotova O, Pilgaard K, Wierup N, Salehi A, Wendt A, Jonsson A, De Marinis YZ, Berglund LM, Taneera J, Balhuizen A, Hansson O, Osmark P, Duner P, Brons C, Stancakova A, Kuusisto J, Bugliani M, Saxena R, Ahlqvist E, Kieffer TJ, Tuomi T, Isomaa B, Melander O, Sonestedt E, Orho-Melander M, Nilsson P, Bonetti S, Bonadonna R, Miccoli R, Delprato S, Marchetti P, Madsbad S, Poulsen P, Vaag A, Laakso M, Gomez MF, Groop L. 2011. Pleiotropic effects of GIP on islet function involve osteopontin. Diabetes 60:2424- 2433. http://dx.doi.org/10.2337/db10-1532.
57. Jorde R, Schulz TB, Burhol PG, Waldum HL. 1982. Effect of gastrin on fasting and postprandial plasma GIP release in man. Digestion 25:81-87. http://dx.doi.org/10.1159/000198815.
58. Ahlqvist E, Osmark P, Kuulasmaa T, Pilgaard K, Omar B, Brons C, Kotova O, Zetterqvist AV, Stancakova A, Jonsson A, Hansson O, Kuusisto J, Kieffer TJ, Tuomi T, Isomaa B, Madsbad S, Gomez MF, Poulsen P, Laakso M, Degerman E, Pihlajamaki J, Wierup N, Vaag A, Groop L, Lyssenko V. 2013. Link between GIP and osteopontin in adipose tissue and insulin resistance. Diabetes 62:2088-2094. http://dx.doi .org/10.2337/db12-0976.
59. Kim SJ, Nian C, McIntosh CH. 2010. GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene. J. Lipid Res. 51:3145-3157. http://dx.doi.org/10.1194/jlr .M006841.
60. Tseng CC, Boylan MO, Jarboe LA, Usdin TB, Wolfe MM. 1996. Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. Am. J. Physiol. 270:E661-E666.
61. Vilsboll T, Krarup T, Madsbad S, Holst JJ. 2002. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45:1111-1119. http://dx.doi.org/10.1007 /s00125-002-0878-6.
62. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. 1993. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91:301-307. http://dx .doi.org/10.1172/JCI116186.
63. Zhou J, Livak MF, Bernier M, Muller DC, Carlson OD, Elahi D, Maudsley S, Egan JM. 2007. Ubiquitination is involved in glucosemediated downregulation of GIP receptors in islets. Am. J. Physiol. Endocrinol. Metab. 293:E538-E547. http://dx.doi.org/10.1152/ajpendo.00070 .2007.
64. Fortin JP, Schroeder JC, Zhu Y, Beinborn M, Kopin AS. 2010. Pharmacological characterization of human incretin receptor missense variants. J. Pharmacol. Exp. Ther. 332:274-280. http://dx.doi.org/10.1124 /jpet.109.160531.
65. Luo R, Jin Z, Deng Y, Strokes N, Piao X. 2012. Disease-associated mutations prevent GPR56-collagen III interaction. PLoS One 7:e29818. http://dx.doi.org/10.1371/journal.pone.0029818.
66. Chiang NY, Hsiao CC, Huang YS, Chen HY, Hsieh IJ, Chang GW, Lin HH. 2011. Disease-associated GPR56 mutations cause bilateral frontoparietal polymicrogyria via multiple mechanisms. J. Biol. Chem. 286:14215- 14225. http://dx.doi.org/10.1074/jbc.M110.183830.
67. Sanchez-Laorden BL, Herraiz C, Valencia JC, Hearing VJ, Jimenez- Cervantes C, Garcia-Borron JC. 2009. Aberrant trafficking of human melanocortin 1 receptor variants associated with red hair and skin cancer: steady-state retention of mutant forms in the proximal Golgi. J. Cell. Physiol. 220:640-654. http://dx.doi.org/10.1002/jcp.21804.
68. Xiang Z, Proneth B, Dirain ML, Litherland SA, Haskell-Luevano C. 2010. Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortinderived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist. Biochemistry 49:4583-4600. http://dx.doi.org/10 .1021/bi100068u.
69. Granell S, Mohammad S, Ramanagoudr-Bhojappa R, Baldini G. 2010. Obesity-linked variants of melanocortin-4 receptor are misfolded in the endoplasmic reticulum and can be rescued to the cell surface by a chemical chaperone. Mol. Endocrinol. 24:1805-1821. http://dx.doi.org/10.1210 /me.2010-0071.